Satin L S
Department of Pharmacology and Toxicology, Medical College of Virginia School of Medicine, Virginia Commonwealth University, Box 980524, 23298-0524, Richmond, VA.
Endocrine. 1996 Jun;4(3):191-8. doi: 10.1007/BF02738684.
Oral antidiabetic sulfonylureas like tolbutamide and glyburide have been used to treat patients with noninsulin dependent diabetes mellitus. These agents lower blood glucose by stimulating insulin secretion from the pancreatic islets of Langerhans. A major component of this stimulation is sulfonylurea-mediated closure of the ATP-inhibited potassium channels (K(ATP) channels) of islet β-cells. Closure of these channels leads to cell depolarization, calcium uptake, and insulin exocytosis. Progress leading up to the recent cloning of the high-affinity sulfonylurea receptor and reconstitution of the K(ATP) channel is reviewed in this article together with new data showing that sulfonylureas may control secretion by activating a novel chloride ion channel, inhibiting an islet Na/K/ATPase or via distal stimulation of granule exocytosis by a kinase C dependent mechanism.
口服抗糖尿病磺脲类药物,如甲苯磺丁脲和格列本脲,已被用于治疗非胰岛素依赖型糖尿病患者。这些药物通过刺激胰岛β细胞分泌胰岛素来降低血糖。这种刺激的一个主要成分是磺脲类药物介导的胰岛β细胞ATP抑制钾通道(K(ATP)通道)的关闭。这些通道的关闭导致细胞去极化、钙摄取和胰岛素胞吐作用。本文回顾了导致最近高亲和力磺脲类受体克隆和K(ATP)通道重组的进展,以及新的数据表明磺脲类药物可能通过激活一种新型氯离子通道、抑制胰岛钠/钾/ATP酶或通过蛋白激酶C依赖机制对颗粒胞吐作用进行远端刺激来控制分泌。